[HTML][HTML] Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu… - …, 2024 - thelancet.com
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
[PDF][PDF] Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu, N Zhang… - 2024 - scienceopen.com
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu… - …, 2024 - europepmc.org
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
[HTML][HTML] Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu, N Zhang… - eClinicalMedicine, 2024 - Elsevier
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin… - …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
[HTML][HTML] Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu… - …, 2024 - ncbi.nlm.nih.gov
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
S Wang, J Sun, X Zhang, M Li, B Qin, M Liu… - …, 2024 - europepmc.org
Background Azvudine and nirmatrelvir/ritonavir are approved to treat mild-to-moderate
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …
coronavirus disease 2019 (COVID-19) in adults with a high risk for progression to severe …